pI: 6.5016 |
Length (AA): 527 |
MW (Da): 56521 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 525 | 4bby (A) | 90 | 658 | 26.00 | 0 | 1 | 1.2658 | 0.13 |
1 | 519 | 5ae2 (A) | 90 | 652 | 27.00 | 0 | 1 | 1.27112 | 0.2 |
25 | 151 | 5khn (B) | 577 | 697 | 35.00 | 0.88 | 0.26 | 0.247787 | 1.71 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Dormant phase. | murphy |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Dormant phase. | hasan |
murphy | Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. |
hasan | Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. |
Ortholog group members (OG5_130256)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_07035 | alkyldihydroxyacetonephosphate synthase |
Caenorhabditis elegans | CELE_Y50D7A.7 | Protein ADS-1 |
Dictyostelium discoideum | DDB_G0286183 | alkyl-dihydroxyacetonephosphate synthase |
Drosophila melanogaster | Dmel_CG10253 | CG10253 gene product from transcript CG10253-RB |
Escherichia coli | b4463 | putative FAD-containing dehydrogenase |
Homo sapiens | ENSG00000018510 | alkylglycerone phosphate synthase |
Leishmania braziliensis | LbrM.30.0130 | alkyldihydroxyacetonephosphate synthase |
Leishmania donovani | LdBPK_300120.1 | alkyldihydroxyacetonephosphate synthase |
Leishmania infantum | LinJ.30.0120 | alkyldihydroxyacetonephosphate synthase |
Leishmania major | LmjF.30.0120 | alkyldihydroxyacetonephosphate synthase |
Leishmania mexicana | LmxM.29.0120 | alkyl dihydroxyacetonephosphate synthase |
Loa Loa (eye worm) | LOAG_04268 | alkyldihydroxyacetonephosphate synthase |
Mus musculus | ENSMUSG00000042410 | alkylglycerone phosphate synthase |
Mycobacterium tuberculosis | Rv3107c | Possible alkyldihydroxyacetonephosphate synthase AgpS (alkyl-DHAP synthase) (alkylglycerone-phosphate synthase) |
Mycobacterium tuberculosis | Rv2251 | Possible flavoprotein |
Mycobacterium ulcerans | MUL_1298 | flavoprotein |
Schmidtea mediterranea | mk4.000265.05 | Alkyldihydroxyacetonephosphate synthase |
Trypanosoma brucei gambiense | Tbg972.6.1150 | alkyl-dihydroxyacetone phosphate synthase,alkyl-DHAP synthase,alkylglycerone-phosphate synthase |
Trypanosoma brucei | Tb927.6.1500 | alkyl-dihydroxyacetone phosphate synthase |
Trypanosoma congolense | TcIL3000_0_37370 | alkyl-dihydroxyacetone phosphate synthase |
Trypanosoma congolense | TcIL3000_6_980 | alkylglycerone-phosphate synthase, putative |
Trypanosoma cruzi | TcCLB.505807.110 | alkyl-dihydroxyacetone phosphate synthase, putative |
Trypanosoma cruzi | TcCLB.503815.10 | alkyl-dihydroxyacetone phosphate synthase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
this record | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu2286 | Mycobacterium tuberculosis | essential | nmpdr |
Tb927.6.1500 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.1500 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.1500 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.6.1500 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b4463 | Escherichia coli | non-essential | goodall |
CELE_Y50D7A.7 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_Y50D7A.7 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_Y50D7A.7 | Caenorhabditis elegans | slow growth | wormbase |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3